Kura Oncology to Participate in Two Upcoming Investor Conferences
November 23, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Kura Oncology, Inc.
– Continued enrollment in Phase 1b study of menin inhibitor KO-539 in NPM1-mutant and KMT2A-rearranged relapsed/refractory AML – – ASH presentation to highlight molecular mechanisms of activity for...
Kura Oncology to Participate in Credit Suisse Healthcare Conference
November 02, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Third Quarter 2021 Financial Results
October 28, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Appoints Teresa Bair as Chief Legal Officer
October 18, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Two Upcoming Investor Conferences
September 07, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Second Quarter 2021 Financial Results
August 05, 2021 16:05 ET
|
Kura Oncology, Inc.
– First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 – – Clinical collaboration with Novartis to evaluate tipifarnib in combination with the PI3Kα inhibitor alpelisib in...
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
August 04, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Second Quarter 2021 Financial Results
July 29, 2021 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Appoints Helen Collins, M.D. to Board of Directors
July 29, 2021 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...